Xiao-Wei Ma, Xiao-Hui Guo, Xin-Hua Xiao, Li-Xin Guo, Xiao-Feng Lv, Quan-Min Li, Yan Gao. A randomized, open-label, multicentre study to evaluate plasma atherosclerotic biomarkers in patients with type 2 diabetes mellitus and arteriosclerosis obliterans when treated with Probucol and Cilostazol[J]. Journal of Geriatric Cardiology, 2012, 9(3): 228-236. DOI: 10.3724/SP.J.1263.2012.02143
Citation: Xiao-Wei Ma, Xiao-Hui Guo, Xin-Hua Xiao, Li-Xin Guo, Xiao-Feng Lv, Quan-Min Li, Yan Gao. A randomized, open-label, multicentre study to evaluate plasma atherosclerotic biomarkers in patients with type 2 diabetes mellitus and arteriosclerosis obliterans when treated with Probucol and Cilostazol[J]. Journal of Geriatric Cardiology, 2012, 9(3): 228-236. DOI: 10.3724/SP.J.1263.2012.02143

A randomized, open-label, multicentre study to evaluate plasma atherosclerotic biomarkers in patients with type 2 diabetes mellitus and arteriosclerosis obliterans when treated with Probucol and Cilostazol

  • Objectives To evaluate the plasma atherosclerotic biomarkers in patients with type 2 diabetes mellitus (T2DM) and arteriosclerosis obliteran (ASO) when treated with Probucol plus Cilostazol in combination and individually. Methods In this open-label study, patients aged 40–75 years were randomized to receive conventional therapy alone, or with Cilostazol 100 mg bid, or with Probucol 250 mg bid, or with both in combination. Endpoints included changes in plasma biomarker and safety at 12 weeks. Results Of the 200 randomized pati?ents, 165 for per-protocol and 160 for the safety (QTc intervals) were set, respectively. Probucol significantly reduced total cholesterol (P P = 0.01), and high-density lipoprotein cholesterol (HDL-C) (P P = 0.002) and reducing triglycerides levels (P P = 0.065). No significant effects on the majority of the remaining biomarkers were found across the treatment groups. Conclusions We have confirmed that Ox-LDL could be a possible plasma atherosclerotic biomarker among the evaluated biomarkers, which reflected the synergetic effect of Cilostazol plus Probucol in patients with T2DM and ASO shown previously in preclinical studies.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return